INTRODUCTION
In contrast to the lifelong response to levodopa treatment in most patients with Parkinson's disease (PD), 1, 2 only 30% of patients with multiple system atrophy (MSA) respond to levodopa treatment. 3, 4 Such favorable response usually does not last longer than 3 years, and only 10% of the patients with MSA enjoy lifelong responsiveness. 3, 5, 6 Therefore, objective measurement of the response to levodopa may provide a clue for the differential diagnosis between the two most common parkinsonian syndromes and may help to avoid unnecessary levodopa treatment.
Several postmortem pathological studies of patients with MSA reported that the response to levodopa treatment correlates with the degree of degeneration of striatal neurons. [7] [8] [9] [10] [11] However, they were retrospective studies judged the amount of response to levodopa treatment based on the patients' reports or physician's impressions. An to levodopa treatment in MSA patients. 12 This was also a retrospective study in which subjective criteria for levodopa responsiveness was omitted. Here, we studied the striatal and cerebellar glucose metabolism on FDG PET studies and short-term response to levodopa treatment prospectively.
MATERIALS AND METHODS

Subjects
From June 2004 to December 2005, we enrolled 39 patients with MSA who fulfilled the Gilman's diagnostic criteria of probable MSA. 13 We excluded the patients who showed cerebrovascular lesions on brain magnetic resonance imaging (MRI) studies and who could not take levodopa because of the side effects. We also included 16 age matched controls for the comparison of striatal and cerebellar glucose metabolism. The written-informed consent about the invasive procedure was obtained from all subjects included.
Evaluation of the patients
Unified Parkinson's Disease Rating Scale (UPDRS) motor score was measured and two timed motor tests were performed before and after levodopa treatment. We modified the Core Assessment Program for Intracerebral Transplantations (CAPIT) protocol. 14 We measured the time taken to finish touching two points separated by 20 cm apart with each hand and foot for ten times. We also measured the time required to stand up from a chair, walk 5 m, turn, walk back to the chair and sit (stand-walk-sit test). For another timed motor test, Purdue peg board test was performed. 15 Patients were instructed to put the pins into the holes using each hand and with both hands.
Also, the task assembling the pin, washer and collar were performed with both hands. 
Quantitative brain FDG PET study
The subjects fasted overnight prior to the FDG PET 
RESULTS
Characteristics of patients
The had never been treated with dopaminergic medications.
At baseline, the mean UPDRS motor score was 26.1±9.6
(range: 4 to 44). 
Improvement of UPDRS motor scores and timed motor tests
Comparison of rCMRglu of striatum and cerebellum between the patients with MSA and normal controls
The rCMRglu values of all measured VOIs of patients with MSA were significantly lower than those of controls.
When we divided the patients with MSA into the MSA-P and MSA-C and compared each group with controls, both groups of patients showed significantly lower rCMRglu values in all VOIs than those of controls (Fig. 1 ).
Brain regions correlated with the clinical improvements analyzed by SPM2
(A) (B) (C) (D) The improvements in Purdue peg board tests correlated with the glucose metabolism in the cerebellar cortex and vermis (uncorrected p<0.001). When we adopted the level of significance at uncorrected p<0.01, the improvements of UPDRS score and modified CAPIT test by the levodopa treatment showed tendency of correlation with the glucose metabolism of the cerebellar cortex and vermis (Fig. 2) .
Correlations between the clinical improvements
and the rCMRglu of striatum and cerebellum analyzed by template VOIs (Fig. 3, Table 1 ).
DISCUSSION
Striatal glucose metabolism and the responsiveness to levodopa
The akinesia of the parkinsonian rats induced by 6-hydroxydopamine responded well to levodopa treatment.
Subsequent intrastriatal injection of quinolinic acid to destroy the striatal neurons ameliorated the beneficial effect of levodopa treatment. 17 Also, in non-human primates with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)
induced parkinsonism responded to levodopa treatment.
Subsequent chronic administration of 3-nitropropionic acid abolished levodopa responsiveness.
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In retrospective clinicopathological studies of the patients with MSA, poor levodopa responsiveness has been attributed to the degeneration of the striatal neurons.
7-11
There were several patients with MSA who showed levodopa induced dyskinesia and excellent response to levodopa treatment for up to 9 years. They had minimal striatal damage in postmortem pathological studies. [19] [20] [21] [22] Therefore, the integrity of the postsynaptic striatal neuron was thought to be associated with the responsiveness to levodopa treatment.
In accordance with the previous animal studies and clinicopathological reports, the present study showed a correlation between the improvement of UPDRS motor score and the rCMRglu of the VOI of posteriorputamen. the striatal glucose metabolism and the degree of parkinsonian motor deficits. 23 In the present study, we also could not find any correlation between the UPDRS motor score and the glucose metabolism in the putamen.
Cerebellar glucose metabolism and the responsiveness to levodopa
Most previous clinicopathological reports focused on the degree of striatal pathology and the responsiveness to levodopa treatment. [7] [8] [9] [10] [11] In the present study, cerebellar glucose metabolism was associated more closely with clinical improvement after levodopa treatment than that of the striatum. In a postmortem pathological study, patients with striatonigral degeneration (SND) type MSA showed favorable response to levodopa treatment more frequently than those with olivopontocerebellar atrophy type MSA. Also, in MSA patients with similar degree of SND pathology, those with higher grade cerebellar damage responded less well to levodopa treatment. 24 The presence of akinesia was inversely related to the cell loss in the inferior olive, pontine nuclei and cerebellar cortex. 3 Although the patients with MSA-C also had SND pathology, they usually do not exhibit parkinsonian features corresponding to the degree of damage to the striatum. 24 In such patients, parkinsonian rigidity seemed to be offset by cerebellar hypotonia. 25 In contrast, patients with cerebellar deficits may show delayed initiation and execution of movement similar to those with basal ganglia damage. 26 In patients with MSA, the cerebellar damage may augment parkinsonian clumsiness and slowness of movement, which certainly influence UPDRS motor score and timed motor tests. Such cerebellar bradykinesia may not be improved by the levodopa treatment. Therefore, the amount of the improvement of parkinsonian motor deficits observed in MSA with cerebellar dysfunction may be decreased by those reasons.
Conclusion
